However, the inability of broad-spectrum MMP inhibition to successfully provide clinical translation has led to renewed interest in the elaboration of MMP inhibitors that exhibit narrow specificity, as has been successfully demonstrated in atherosclerosis studies utilising inhibitors restricted to the targeting of MMP-12 (101) or MMP-13 (190). This evidence concerns the gene MMP12 and atherosclerosis.